Gaelen Snell

Canada has committed to eliminating viral hepatitis as a major public health threat by 2030, setting benchmarks to reduce new hepatitis C virus (HCV) cases by 90% and ensure that 80% of eligible people receive treatment (1). Direct-acting antiviral (DAA) therapies cure greater than 90% of cases, and without a vaccine against HCV, are key to achieving elimination targets (2–4). As such, DAA access is essential to deliver on Canada’s commitment to HCV elimination.